OBI Pharma (ROCO:4174) Debt-to-Asset : 0.09 (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is OBI Pharma Debt-to-Asset?

OBI Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was NT$90.16 Mil. OBI Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was NT$415.01 Mil. OBI Pharma's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was NT$5,653.69 Mil. OBI Pharma's debt to asset for the quarter that ended in Dec. 2024 was 0.09.

OBI Pharma Debt-to-Asset Historical Data

The historical data trend for OBI Pharma's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OBI Pharma Debt-to-Asset Chart

OBI Pharma Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Asset

Get a 7-Day Free Trial

0.05

0.07

0.04

0.09

OBI Pharma Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Asset	Get a 7-Day Free Trial															0.09	0.10	0.11	0.13	0.09

Competitive Comparison of OBI Pharma's Debt-to-Asset

For the Biotechnology subindustry, OBI Pharma's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OBI Pharma's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OBI Pharma's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where OBI Pharma's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

OBI Pharma Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

OBI Pharma's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(90.159	+	415.007)	/	5653.692
	=	0.09

OBI Pharma's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(90.159	+	415.007)	/	5653.692
	=	0.09

OBI Pharma (ROCO:4174) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

OBI Pharma Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of OBI Pharma's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

OBI Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OBI Pharma Inc (ROCO:4174) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 508, Section. 7, Zhongxiao East Road, 6th Floor, Nangang District, Taipei, TWN, 115011

Website

https://www.obipharma.com

OBI Pharma Inc is a clinical-stage oncology company. It focuses on research and development for cancer therapies and aims to develop ground-breaking drugs. The core value lies in its passion to develop and deliver a portfolio of antibody-drug conjugates (ADCs) drugs for patients, in addition to its Globo H active immunotherapy. Its portfolio includes a spectrum of cancer targets, such as TROP2, Nectin-4, HER2, and other potential targets. These ADCs are built based on two distinct ADC technology platforms, with different characteristics. It offers a plug-and-play advantage through a specialized site-specific conjugation using a proprietary enzyme. Its segments are the anti-cancer new drug; bispecific monoclonal antibody new drug; botulinum toxin new drug; and CDMO segment.

OBI Pharma Headlines

No Headlines